Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
NPCE
#2547
Neuropace, Inc. Common Stock
14.580
0
-0.95%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-0.95%
Changement Mensuel
-9.97%
Evolution sur 6 mois
+37.81%
Changement Annuel
+37.81%
Clôture Précédente
14.720
0
Open
14.580
0
Bid
Ask
Low
14.580
0
High
14.580
0
Volume
30
Marchés
Actions des Marchés US
Soins de Santé
NPCE
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
24.47 M
25.1 M
28.34 M
32.56 M
—
Valuation ratios
Enterprise value
227.48 M
29.54 M
259.15 M
350.92 M
1.4 B
Price to earnings ratio
-4.65
-0.75
-7.7
-12.03
-54.54
Price to sales ratio
3.71
0.78
3.86
4.08
15.61
Price to cash flow ratio
-6.81
-0.96
-12.83
-18.16
-79.39
Price to book ratio
2.28
1.02
12.24
40.67
58.01
Enterprise value to EBITDA ratio
-9.82
-0.73
-9.71
-16.52
-72.34
Profitability ratios
Return on assets %
0.27
0.41
0.31
0.29
0.23
Return on equity %
0.49
1.35
1.6
3.39
1.56
Return on invested capital %
1 195.31
1 140.71
494.27
416.78
—
Gross margin %
74
71.38
73.56
73.94
306.88
Operating margin %
52.54
89.62
41.54
27.12
78.39
EBITDA margin %
-51.28
-88.39
-40.8
-26.58
-76.65
Net margin %
79.85
103.43
50.38
33.97
103.27
Liquidity ratios
Quick ratio
13.44
8.02
5.02
4.48
18.64
Current ratio
14.28
8.9
5.71
5.37
22.33
Inventory turnover
1.5
1.49
1.65
1.69
1.52
Asset turnover
0.34
0.37
0.59
0.79
0.92
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
0.37
0.46
0.53
0.63
2.27
Long term debt to total equity ratio
0.68
1.52
2.76
7.43
16.08
Per share metrics
Operating cash flow per share
1.48
1.5
0.76
0.61
0.52
EBIT per share
-1.43
-1.66
-1.05
-0.74
-0.58
EBITDA per share
-1.4
-1.64
-1.03
-0.73
-0.56
Total debt per share
—
—
—
—
—
Cash per share
6.96
3.15
2.57
1.81
7.62
Net current asset value per share
8
3.97
3.59
2.79
11.62
Tangible book value per share
4.43
1.41
0.8
0.28
2.2
Working capital per share
7.44
3.53
2.96
2.27
9.52
Book value per share
4.43
1.41
0.8
0.28
2.2
Nouvelles
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
L’objectif de prix de l’action NeuroPace relevé à 20$ contre 19$ par Leerink Partners
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
L’objectif de prix de l’action NeuroPace relevé à 19$ contre 18$ par H.C. Wainwright
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Le titre de NeuroPace grimpe alors qu’UBS réitère sa recommandation d’achat
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
NeuroPace annonce une croissance de 25% de son chiffre d’affaires pour 2025